Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis

MLA

Mattli, Renato, et al. Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1373798901&authtype=sso&custid=ns315887.

APA

Mattli, R., Grobet, C., Sharakin, M., Pöhlmann, J., Vinci, L., Syleouni, M.-E., Carlander, M., Meier, F., Egli, P., Gerber-Grote, A., & Wieser, S. (2023). Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis.

Chicago

Mattli, Renato, Cécile Grobet, Maxim Sharakin, Johannes Pöhlmann, Linda Vinci, Maria-Eleni Syleouni, Maria Carlander, et al. 2023. “Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1373798901&authtype=sso&custid=ns315887.